The first infusion of an investigational drug that aims to delay or help to prevent the earliest memory loss due to Alzheimer’s disease took place in September at Butler Hospital in Providence, R.I., researchers announced.
Sam Slezak originally set out to become a trainer for professional athletes. Here’s how and why he became a project manager for a landmark national Alzheimer’s study instead.
AHEAD 3-45 is a clinical trial for a treatment aimed at preventing cognitive decline in people with preclinical Alzheimer’s Disease (AD).
MAP Director Dr. Stephen Salloway, along with other international leaders in the fight against Alzheimer’s, talk with the Providence Journal and WJAR NBC10 about how the fight to end Alzheimer’s continues despite coronavirus.
New Data for Investigational Drug for Early-Onset Alzheimer’s Illustrates Value of “Failed” Research Studies
Initial results in a clinical trial aimed at early-onset Alzheimer’s didn’t look promising – but upon further review, the data has spurred further study.
Major Alzheimer’s Association grant to enable researchers to test a drug that could slow the progression of Alzheimer’s disease.
With a special combination of compassionate care and scientific inquiry, she’s part of the front-line fight to end Alzheimer’s.
Drug Studied at Butler Hospital’s Memory and Aging Program May Become First New Treatment for Alzheimer’s in 16 Years
Aducanumab maker Biogen seeking FDA review in early 2020; if approved, it will become the first drug to remove amyloid protein from the brain and slow the progression of Alzheimer’s disease (AD).
A look inside the Memory and Aging Program at Butler Hospital and how Southern New Englanders are contributing to the mounting battle against Alzheimer’s.
Clinical Trials Aimed at Preventing Alzheimer’s to Begin at Butler Hospital’s Memory and Aging Program
The Memory and Aging Program at Butler Hospital will launch trials of two new treatments aimed at preventing Alzheimer’s in early 2020.